|
시장보고서
상품코드
2058286
간질 발작 치료 시장 : 약제 종류별, 발작 종류별, 투여 경로별, 유통 채널별, 지역별Epileptic Seizures Treatment Market, By Drug Type, By Seizure Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
간질 발작 치료 시장은 2026년에 42억 달러로 추정되며, 2033년까지 61억 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 5.6%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 42억 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 5.60% | 2033년 시장 규모 예측: | 61억 달러 |
간질은 뚜렷한 원인 없이 반복적으로 발작을 일으키는 만성 질환입니다. 발작이란 뇌 내에서 전기적 활동이 갑자기 활발해지는 현상입니다. 간질은 발작이라고 불리는 뇌 활동 장애와 관련이 있으며, 중추 신경계에 영향을 미칩니다. 간질은 뇌의 어느 부위가 영향을 받느냐에 따라 전신 발작과 부분 발작으로 분류됩니다. 간질 환자 수의 증가가 전 세계 간질 발작 치료 시장의 성장을 견인할 것으로 예상됩니다. 예를 들어, Epilepsy Action Australia의 2017년 통계 조사에 따르면 전 세계적으로 약 5,000만 명이 간질을 앓고 있으며, 그 중 약 80%가 인도, 브라질, 중국 등의 신흥 경제국에 거주하고 있는 것으로 나타났습니다.
또한, 간질 치료제의 출시가 늘어나고 있는 것이 시장 성장에 유리한 환경을 조성할 것으로 예상됩니다. 예를 들어, 2016년에는 UCB Pharma Limited가 부분 발작 환자용 치료제 '브리비액트(Briviact)'에 대해 미국 식품의약국(FDA)의 승인을 획득했습니다. 또한, 마일란(Mylan)사는 2016년 미국 식품의약국(FDA)의 승인을 받은 후, 간질 발작 치료제인 제네릭 의약품 '펠바톨(Felbatol) 정'을 미국에서 출시했습니다. 이러한 요인들이 예측 기간 동안 시장 성장을 견인할 것으로 전망됩니다.
시장 역학
전 세계적으로 성인 및 소아의 간질 유병률이 증가하고 있는 점이 예측 기간 동안 간질 발작 치료 시장의 성장을 견인할 것으로 예상됩니다. WHO에 따르면, 간질을 앓고 있는 소아의 약 3분의 1은 간질 증후군 분류에 관한 최신 제안 체계에 따라 특정 간질 증후군으로 분류될 수 있습니다. 미국신경과학회(Society of Neuroscience)에 따르면, 2015년 전 세계적으로 약 1,050만 명의 어린이가 간질에 걸려 있었으며, 그 종류와 중증도는 크게 달랐습니다. 또한, 2017년 4월에 발표된 미국소아과학회(American Academy of Pediatrics)의 자료에 따르면, 간질은 전 세계 소아의 0.5%에서 1%에 영향을 미치고 있으며, 소아기에 가장 흔하게 발생하는 만성 신경 질환입니다.
그러나 비전통적인 항경련 치료나 비약물 요법은 발작을 완화하거나 항경련제의 부작용을 줄이는 데 도움이 될 수 있습니다. 예를 들어, 소아 치료 분야에서 코르티코스테로이드, 면역글로불린, 멜라토닌, 비타민 등 간질에 대한 대체 요법이 점점 더 선호되고 있습니다. 보조 요법 외에도 발작을 유발할 가능성이 있는 활동(깜빡이는 빛, 특정 종류의 음악이나 곡 감상, 식사, 독서, 온수 목욕, 체스 대국, 또는 머리 빗기 등)을 피하는 '회피법'과 같이, 간질 발작을 완화하는 데 도움이 되는 특정 기법들이 있습니다. 따라서 이러한 요인들이 간질 발작 치료 시장의 성장을 저해할 것으로 예상됩니다. 소아 뇌전증의 기타 비약물적 치료법으로는 한방약, 동종요법, 요가, 아로마테라피, 그리고 대처법 등이 있습니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하고 있는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음의 주요 지표를 바탕으로 전 세계 간질 발작 치료 시장의 주요 기업들을 분석하고 있습니다 : 기업 개요, 재무 실적, 제품 포트폴리오, 사업 전개 지역, 유통 전략, 주요 발전 사항 및 전략.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 정부의 정책, 기술 업그레이드, 시장 확대 및 마케팅 전략과 관련하여 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 '세계 간질 발작 치료 시장 보고서'는 투자자, 제품 제조사, 유통업체, 공급업체를 비롯해 조사·컨설팅 회사, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
목차
제1장 조사 목적과 가정
제2장 시장 개요
제3장 시장 역학·규제·동향 분석
제4장 세계의 간질 발작 치료 시장 : 약물 유형별, 2021-2033년
제5장 세계의 간질 발작 치료 시장 : 발작 종류별, 2021-2033년
제6장 세계의 간질 발작 치료 시장 : 투여 경로별, 2021-2033년
제7장 세계의 간질 발작 치료 시장 : 유통 채널별, 2021-2033년
제8장 세계의 간질 발작 치료 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 섹션
KSM 26.06.19Epileptic Seizures Treatment Market is estimated to be valued at USD 4.2 Bn in 2026 and is expected to reach USD 6.1 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 4.2 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.60% | 2033 Value Projection: | USD 6.1 Bn |
Epilepsy is a chronic disorder that causes unprovoked and recurrent seizures. A seizure is a sudden rush of electrical activity in the brain. Epilepsy is associated with disrupted activities in the brain called seizures, which affects the central nervous system. Epilepsy is categorized into generalized seizures and partial seizures based on the areas affected in the brain. An increasing number of epilepsy cases is expected to drive growth of the global epileptic seizures treatment market. For instance, according to the study by Epilepsy Action Australia statistics in 2017, around 50 million people globally had epilepsy with around 80% of the people living in emerging economies such as India, Brazil, and China.
Moreover, increasing launches of drugs for treatment of epilepsy is expected to create conducive environment for the market growth. For instance, in 2016, UCB Pharma Limited received the U.S. FDA approval for Briviact, for the treatment of patients with partial onset of seizures. Moreover, Mylan launched generic, Felbatol tablets for the treatment of epileptic seizures, in the U.S. after receiving approval from the U.S. Food & Drug Administration in 2016. These factors are expected to boost the market growth over the forecast period.
Market Dynamics
The increasing prevalence of epilepsy in adults and children, across the globe is expected to drive growth of the epileptic seizures treatment market during the forecast period. According to the WHO, around one-third of children with epilepsy can be assigned to a specific epilepsy syndrome, as defined by the most recently proposed system for organization of epilepsy syndrome. According to the Society of Neuroscience, in 2015, epilepsy affected around 10.5 million children worldwide, and the types and severity of the disorder varied significantly. Moreover, according to the American Academy of Pediatrics data published in April 2017, epilepsy affects 0.5% to 1% of children globally, and is the most frequently occurring chronic neurologic condition in childhood.
However, nonconventional anti-epileptic treatments and nonpharmacological approaches can potentially help in reduction of seizures or anti-epileptic drug toxicity. For instance, there has been increasing preference for alternative therapy for epilepsy such as corticosteroids, immunoglobulins, melatonin, and vitamins for treating children. Other than supplemental therapy, there are certain techniques that can help reduce epileptic seizures such as avoidance technique, which involves avoiding activities that can induce a seizure such as flickering lights, listening to specific type or piece of music, eating, reading, and immersion in hot water, chess playing, or brushing hair. Thus, these factors are expected to restrain the epileptic seizures treatment market growth. Other nonpharmacological treatments for epilepsy in children include herbal medicine, homeopathy, yoga, aromatherapy, and coping strategies.
Key features of the study
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global epileptic seizures treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A., Mylan N.V., Bausch Health Companies Inc., UCB S.A., Eisai Co. Ltd., Abbott Laboratories, Sumitomo Dainippon Pharma Co., Ltd., GW Pharmaceuticals Plc, Marinus Pharmaceuticals, Inc., H. Lundbeck A/S, and Takeda Pharmaceutical Co., Ltd.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global epileptic seizures treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for epileptic seizures treatment market, research and consulting firms, new entrants, and financial analysts.
Market Segmentation
- By Drug Type Insights (Revenue, USD Bn, 2021 - 2033)
- First Generation
- Second Generation
- Third Generation
- By Seizure Type Insights (Revenue, USD Bn, 2021 - 2033)
- Partial Seizures
- Generalized Seizures
- Unclassified Seizures
- By Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral/Buccal
- Nasal
- Rectal
- Parenteral
- By Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players
- Novartis AG
- GlaxoSmithKline Plc
- Johnson & Johnson Service, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Sanofi S.A.
- Mylan N.V.
- Bausch Health Companies Inc.
- UCB S.A.
- Eisai Co. Ltd.
- Abbott Laboratories
- Sumitomo Dainippon Pharma Co., Ltd.
- GW Pharmaceuticals Plc
- Marinus Pharmaceuticals, Inc.
- Lundbeck A/S
- Takeda Pharmaceutical Co., Ltd
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Seizure Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Epidemiology
- Regulatory Scenario
- Reimbursement Scenario
- New Product Launches/Approvals
- Key Developments
- Government Initiatives and Funding
- Collaborations & Partnerships
- PEST Analysis
4. Global Epileptic Seizures Treatment Market, By Drug Type, 2021 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- First Generation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Second Generation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Third Generation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
5. Global Epileptic Seizures Treatment Market, By Seizure Type, 2021 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Partial Seizures
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Generalized Seizures
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Unclassified Seizures
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
6. Global Epileptic Seizures Treatment Market, By Route of Administration, 2021 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral/Buccal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Rectal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
7. Global Epileptic Seizures Treatment Market, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
8. Global Epileptic Seizures Treatment Market, By Region, 2021 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, By Region, 2022 - 2033
- Regional Trends
- North America
- Market Size and Forecast, By Drug Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Seizure Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Billion)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Seizure Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Seizure Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Billion)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Drug Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Seizure Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Market Size and Forecast, By Drug Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Seizure Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Seizure Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, By Country/Region, 2021 - 2033, (US$ Billion)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GlaxoSmithKline Plc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Johnson & Johnson Service, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Sanofi S.A.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Mylan N.V.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bausch Health Companies Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- UCB S.A
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Eisai Co. Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Abbott Laboratories
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Sumitomo Dainippon Pharma Co., Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GW Pharmaceuticals Plc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Marinus Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Lundbeck A/S
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Takeda Pharmaceutical Co., Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Novartis AG
10. Section
- References
- Research Methodology
- About us and Sales Contact
